Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

1. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. (PubMed)

Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. Platinum-based therapy, including cisplatin, carboplatin, oxaliplatin or a combination of these, is used to treat a variety of paediatric malignancies. One of the most significant adverse effects is the occurrence of hearing loss or ototoxicity. In an effort to prevent this ototoxicity, different otoprotective medical interventions have been studied. This review is the third update of a previously (...) published Cochrane Review.To assess the efficacy of medical interventions to prevent hearing loss and to determine possible effects of these interventions on antitumour efficacy, toxicities other than hearing loss and quality of life in children with cancer treated with platinum-based therapy as compared to placebo, no additional treatment or another protective medical intervention.We searched the Cochrane Central Register of Controlled Trials, MEDLINE (PubMed) and Embase (Ovid) to 8 January 2019. We

2019 Cochrane

2. Perspectives on Conversations About Costs of Cancer Care of Breast Cancer Survivors and Cancer Center Staff: A Qualitative Study. (PubMed)

Perspectives on Conversations About Costs of Cancer Care of Breast Cancer Survivors and Cancer Center Staff: A Qualitative Study. Despite recommendations to discuss the cost of care (CoC) with patients with cancer, little formal guidance is available on how to conduct these sensitive conversations in ways that are acceptable to both patients and providers.To explore the perspectives of patients and medical and nonmedical cancer center staff on CoC conversations.In individual interviews (...) , participants were asked to discuss the content of, timing of, and ideal person to hold CoC conversations. Interviews were transcribed verbatim. Content was analyzed to identify emerging essential elements.Division of Preventive Medicine, University of Alabama at Birmingham.42 women aged 60 to 79 years with a history of breast cancer and 20 cancer center staff (6 physicians, 4 nurses, 5 patient navigators, 3 social workers, and 2 billing specialists).Both patients and providers identified reassurance

Full Text available with Trip Pro

2019 Annals of Internal Medicine

3. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. (PubMed)

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. First-line pembrolizumab monotherapy improves overall and progression-free survival in patients with untreated metastatic non-small-cell lung cancer with a programmed death ligand 1 (PD-L1) tumour proportion score (TPS) of 50% or greater. We investigated overall survival after treatment (...) with pembrolizumab monotherapy in patients with a PD-L1 TPS of 1% or greater.This randomised, open-label, phase 3 study was done in 213 medical centres in 32 countries. Eligible patients were adults (≥18 years) with previously untreated locally advanced or metastatic non-small-cell lung cancer without a sensitising EGFR mutation or ALK translocation and with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, life expectancy 3 months or longer, and a PD-L1 TPS of 1% or greater

2019 Lancet

4. ESMO–ESGO Consensus Conference Recommendations on Ovarian Cancer: Pathology and Molecular Biology, Early and Advanced Stages, Borderline Tumours and Recurrent Disease

ESMO–ESGO Consensus Conference Recommendations on Ovarian Cancer: Pathology and Molecular Biology, Early and Advanced Stages, Borderline Tumours and Recurrent Disease SPECIAL ARTICLE ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease † N. Colombo 1 * , C. Sessa 2 , A. du Bois 3 , J. Ledermann 4 , W. G. McCluggage 5 , I. McNeish 6 , P. Morice 7 , S. Pignata 8 , I. Ray-Coquard 9 , I (...) . Vergote 10,11 , T. Baert 3 , I. Belaroussi 7 , A. Dashora 12 , S. Olbrecht 10,11 , F. Planchamp 13 & D. Querleu 14 * , on behalf of the ESMO–ESGO Ovarian Cancer Consensus Conference Working Group ‡ 1 Division of Medical Gynecologic Oncology, European Institute of Oncology IRCCS, University of Milan-Bicocca, Milan, Italy; 2 Department of Medical Oncology, Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland; 3 Department of Gynecology and Gynecologic Oncology

2019 European Society for Medical Oncology

5. Organizational Guidance for the Care of Patients with Head and Neck Cancer in Ontario

Organizational Guidance for the Care of Patients with Head and Neck Cancer in Ontario Guideline 5-3ORG Version 2 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Organizational Guidance for the Care of Patients with Head and Neck Cancer in Ontario J. Irish, J. Kim, J. Waldron, A. Wei, E. Winquist, J. Yoo, A. Boasie, M. Brouwers, E. Meertens, S. McNair, C. Walker-Dilks and the Expert Panel on Organizational Guidance for the Care of Patients with Head (...) and Neck Cancer in Ontario This document is an update of the organizational guidance portion of the 2009 version of the guideline (Evidence-Based Series 5-3 The Management of Head and Neck Cancer in Ontario). Report Date: April 25, 2019 For information about this document, please contact Dr. Jon Irish, the lead author, through the PEBC via: Phone: 905-527-4322 ext. 42822 Fax: 905 526-6775 E-mail: ccopgi@mcmaster.ca For information about the PEBC and the most current version of all reports, please visit

2019 Cancer Care Ontario

6. Prostate cancer: diagnosis and management

Prostate cancer: diagnosis and management Prostate cancer: diagnosis and Prostate cancer: diagnosis and management management NICE guideline Published: 9 May 2019 www.nice.org.uk/guidance/ng131 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When (...) with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Prostate cancer: diagnosis and management (NG131) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 51Contents Contents Overview 4 Who is it for? 4 Recommendations 5

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

7. Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy

Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy Abemaciclib with fulv Abemaciclib with fulvestr estrant for treating ant for treating hormone receptor-positiv hormone receptor-positive, e, HER2-negativ HER2-negative advanced breast cancer e advanced breast cancer after endocrine ther after endocrine therap apy y T echnology appraisal guidance Published: 8 May 2019 www.nice.org.uk/guidance/ta579 © NICE 2019. All (...) -negative advanced breast cancer after endocrine therapy (TA579) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 19Contents Contents 1 Recommendations 4 2 Information about abemaciclib 6 3 Committee discussion 7 New treatment option 7 Clinical management 8 Clinical evidence 8 Adverse effects 9 Network meta-analysis 10 The company's economic model 10 Utility values in the economic model 12 Subsequent treatments

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

8. Enzalutamide for hormone-relapsed non-metastatic prostate cancer

Enzalutamide for hormone-relapsed non-metastatic prostate cancer Enzalutamide for hormone-relapsed non- Enzalutamide for hormone-relapsed non- metastatic prostate cancer metastatic prostate cancer T echnology appraisal guidance Published: 15 May 2019 www.nice.org.uk/guidance/ta580 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent (...) inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 21Contents Contents 1 Recommendations 4 2 Information about

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

9. Clinical practice guidelines for the prevention, early detection and management of colorectal cancer

Clinical practice guidelines for the prevention, early detection and management of colorectal cancer Clinical practice guidelines for the prevention, early detection and management of colorectal cancer - Cancer Guidelines Wiki Skip Links Personal tools Search Navigation Cancer Council guidelines Methodology Hosted cancer guidelines Adolescents and Young Adult (AYA) guidelines Prevention Policies Social links Page actions The guideline recommendations were approved by the Chief Executive Officer (...) , and developed for health professionals practising in an Australian health care setting. This publication reflects the views of the authors and not necessarily the views of the Australian Government. Cite this guideline Cancer Council Australia Colorectal Referring to the large bowel, comprising the colon and rectum. Cancer Guidelines Working Party. Clinical practice guidelines for the prevention, early detection and management of colorectal cancer. Sydney: Cancer Council Australia. [Version URL: , cited

2019 Cancer Council Australia

10. Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation

Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation Durvalumab for treating locally advanced Durvalumab for treating locally advanced unresectable non-small-cell lung cancer unresectable non-small-cell lung cancer after platinum-based chemor after platinum-based chemoradiation adiation T echnology appraisal guidance Published: 1 May 2019 www.nice.org.uk/guidance/ta578 © NICE 2019. All rights reserved. Subject to Notice of rights (...) . They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum- based

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

11. Abemaciclib (Verzenios) For the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with fulvestrant as initial endocrine-based therap

Abemaciclib (Verzenios) For the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with fulvestrant as initial endocrine-based therap 1 1 SMC2179 abemaciclib 50mg, 100mg and 150mg tablets (Verzenios®) Eli Lilly and Company 5 April 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug (...) and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission assessed under the end of life process abemaciclib (Verzenios®) is accepted for restricted use within NHSScotland. Indication under review: For the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with fulvestrant* as initial endocrine-based therapy

2019 Scottish Medicines Consortium

12. Abemaciclib (Verzenios) Women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based t

Abemaciclib (Verzenios) Women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based t 1 Published 13 May 2019 1 SMC2135 abemaciclib 50mg, 100mg and 150mg tablets (Verzenios®) Eli Lilly and Company 5 April 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards (...) and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission abemaciclib (Verzenios®) is accepted for use within NHSScotland. Indication under review: for the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor* as initial endocrine-based therapy, or in women who have

2019 Scottish Medicines Consortium

13. Erdafitinib (Balversa) - To treat adult patients with locally advanced or metastatic bladder cancer

Erdafitinib (Balversa) - To treat adult patients with locally advanced or metastatic bladder cancer Drug Approval Package: Balversa (erdafinitib) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Balversa (erdafinitib) Company: Janssen Biotech, Inc. Application Number: 212018 Approval Date: 04/12/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF

2019 FDA - Drug Approval Package

14. Follow-Up Model of Care for Cancer Survivors: Recommendations for the Delivery of Follow-up Care for Cancer Survivors in Ontario

Follow-Up Model of Care for Cancer Survivors: Recommendations for the Delivery of Follow-up Care for Cancer Survivors in Ontario Follow-Up Model of Care for Cancer Survivors Recommendations for the Delivery of Follow-up Care for Cancer Survivors in Ontario March 2019 Acknowledgements Cancer Care Ontario would like to acknowledge the contribution and expertise of the following groups, committees, and organizations in the development of this document. Survivorship Care Improvement Project Models (...) Govindarajan (Co-Chair), Anita Rombough (Co-Chair), Brenda Fleming, Arlene Howells, Dr. Jennifer Jones, Dr. Ed Kucharski, Dr. Calvin Law, Carrie Liska, Joanne MacPhil, Karen Melenchuk, Lesley Moody, Erin Redwood, Dr. Jonathan Sussman, and Bob Tuck Groups and Organizations • Cancer Care Ontario’s o Breast Cancer Advisory Committee o Clinical Council o Gastrointestinal Cancers Advisory Committee o Genitourinary Cancers Advisory Committee o Patient and Family Advisory Council o Provincial Primary Care

2019 Cancer Care Ontario

15. eUpdate: Gastric Cancer Treatment Recommendations

eUpdate: Gastric Cancer Treatment Recommendations Gastric Cancer Treatment Recommendations | ESMO Welcome to the EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY , the leading European professional organisation for medical oncology. Search Careers at ESMO ESMO Oncology Journals Our journals offer ESMO members and the oncology community a globally visible platform to publish scientific studies, and a highly credible source of educational updates.​ Connect with ESMO Discover ESMO's new social media (...) and easy access to the essential content of the guidelines – PowerPoint slides and PDFs including algorithms, figures and tables – free to download Breast Cancer 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC4) • Prevention and Screening in BRCA Mutation Carriers and Other Breast/Ovarian Hereditary Cancer Syndromes • Primary Breast Cancer Cancers of Unknown Primary Site Cancers of Unknown Primary Site Endocrine and Neuroendocrine Cancers Neuroendocrine Bronchial

2019 European Society for Medical Oncology

16. PET-CT imaging in patients with anal cancer

PET-CT imaging in patients with anal cancer Advice Statement | 1 Advice Statement 03-19 April 2019 Advice Statement 18 F-fluorodeoxyglucose (FDG) positron emission tomography – computed tomography (PET-CT) for routine staging and monitoring of treatment response in patients with anal cancer Advice for NHSScotland In primary tumour staging in patients diagnosed with anal cancer, FDG PET-CT should be considered as an adjunct to clinical assessment and magnetic resonance imaging (MRI) or computed (...) tomography (CT) imaging. For radiotherapy treatment planning in patients with anal cancer, FDG PET-CT should be considered as an adjunct to clinical assessment and MRI or CT imaging. It is not possible to provide advice on the use of FDG PET-CT for monitoring of treatment response in patients with anal cancer due to a lack of studies assessing this outcome. There is uncertainty about the balance of costs and benefits of FDG PET-CT for anal cancer due to a lack of published cost effectiveness studies

2019 SHTG Advice Statements

17. Evidence based practice guidelines for the nutritional management of adult patients with head and neck cancer

Evidence based practice guidelines for the nutritional management of adult patients with head and neck cancer Evidence-based practice guidelines for the nutritional management of adult patients with head and neck cancer - Cancer Guidelines Wiki Skip Links Personal tools Search Navigation Cancer Council guidelines Methodology Hosted cancer guidelines Adolescents and Young Adult (AYA) guidelines Prevention Policies Social links Page actions Cite this guideline Head and Neck Guideline Steering (...) Committee. Evidence-based practice guidelines for the nutritional management of adult patients with head and neck cancer. Sydney: Cancer Council Australia. [Version URL: , cited 2019 May 26]. Available from: . Table of Contents 1. 2. 3. ( ) 4. Clinical questions and evidence based recommendations 4.1 4.2 4.3 4.4 4.5 4.6 4.7 4.8 4.9 5. Appendices 5.1 5.2 5.3 In partnership with Endorsed by Retrieved from " "

2019 Clinical Oncology Society of Australia

18. Risk-reducing medications for primary breast cancer: a network meta-analysis. (PubMed)

Risk-reducing medications for primary breast cancer: a network meta-analysis. Breast cancer is the most frequently occurring malignancy and the second cause of death for cancer in women. Cancer prevention agents (CPAs) are a promising approach to reduce the burden of breast cancer. Currently, two main types of CPAs are available: selective estrogen receptor modulators (SERMs, such as tamoxifen and raloxifene) and aromatase inhibitors (AIs, such as exemestane and anastrozole).To assess (...) the efficacy and acceptability of single CPAs for the prevention of primary breast cancer, in unaffected women, at an above-average risk of developing breast cancer.Using a network meta-analysis, to rank single CPAs, based on their efficacy and acceptability (an endpoint that is defined as the inverse of CPA-related toxicity).We searched the Cochrane Breast Cancer Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, World Health Organization's International

2019 Cochrane

19. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. (PubMed)

Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Multiparametric magnetic resonance imaging (MRI), with or without MRI-targeted biopsy, is an alternative test to systematic transrectal ultrasonography-guided biopsy in men suspected of having prostate cancer. At present, evidence on which test to use is insufficient to inform detailed evidence-based decision-making.To determine the diagnostic accuracy of the index tests MRI only, MRI (...) -targeted biopsy, the MRI pathway (MRI with or without MRI-targeted biopsy) and systematic biopsy as compared to template-guided biopsy as the reference standard in detecting clinically significant prostate cancer as the target condition, defined as International Society of Urological Pathology (ISUP) grade 2 or higher. Secondary target conditions were the detection of grade 1 and grade 3 or higher-grade prostate cancer, and a potential change in the number of biopsy procedures.We performed

2019 Cochrane

20. Robotic versus open radical cystectomy for bladder cancer in adults. (PubMed)

Robotic versus open radical cystectomy for bladder cancer in adults. It has been suggested that in comparison with open radical cystectomy, robotic-assisted radical cystectomy results in less blood loss, shorter convalescence, and fewer complications with equivalent short-term oncological and functional outcomes; however, uncertainty remains as to the magnitude of these benefits.To assess the effects of robotic-assisted radical cystectomy versus open radical cystectomy in adults with bladder (...) cancer.Review authors conducted a comprehensive search with no restrictions on language of publication or publication status for studies comparing open radical cystectomy and robotic-assisted radical cystectomy. The date of the last search was 1 July 2018 for the Cochrane Central Register of Controlled Trials, MEDLINE (1999 to July 2018), PubMed Embase (1999 to July 2018), Web of Science (1999 to July 2018), Cancer Research UK (www.cancerresearchuk.org/), and the Institute of Cancer Research (www.icr.ac.uk

2019 Cochrane